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Objective: To retrospectively evaluate external beam re-
irradiation (re-EBRT) delivered to the prostate/prostatic
bed for local recurrence, after radical or adjuvant/salvage
radiotherapy (RT).
Methods: 32 patients received re-EBRT between Febru-
ary 2008 and October 2013. All patients had clinical/
radiological local relapse in the prostate or prostatic bed
and no distant metastasis. re-EBRT was delivered with
selective RT technologies [stereotactic RT including
CyberKnifeTM (Accuray, Sunnyvale, CA); image-guidance
and intensity-modulated RT etc.]. Toxicity was evaluated
using the Radiation Therapy Oncology Group/European
Organization for Research and Treatment of Cancer
criteria. Biochemical control was assessed according to
the Phoenix definition (NADIR12ngml21).
Results: Acute urinary toxicity: G0, 24 patients; G1, 6
patients; G2, 2 patients. Acute rectal toxicity: G0, 28
patients; G1, 2 patients; and G2, 1 patient. Late urinary
toxicity (evaluated in 30 cases): G0, 23 patients; G1,
6 patients; G2, 1 patient. Late renal toxicity: G0, 25 patients;
G1, 5 patients. A mean follow-up of 21.3months after re-
EBRT showed that 13 patients were free of cancer, 3 were
alive with biochemical relapse and 12 patients were alive
with clinically evident disease. Four patients had died: two
of disease progression and two of other causes.
Conclusion: re-EBRT usingmodern technology is a feasible
approach for local prostate cancer recurrence offering
2-year tumour control in about half of the patients. Toxicity
of re-EBRT is low. Future studies are needed to identify the
patients who would benefit most from this treatment.
Advances in knowledge: Our series, based on experience
in one hospital alone, shows that re-EBRT for local relapse
of prostate cancer is feasible and offers a 2-year cure in
about half of the patients.
Modern external beam irradiation (EBRT) is considered a cor-
nerstone of the radical treatment of localized prostate cancer.
Technological advances have been progressively introduced,
using highly conformed techniques and dose escalation. In
spite of this, the rate of biochemical failure ranges between 33%
and 69%.1–4 New imaging modalities such as 11C-choline
positron emission tomography/CT (PET/CT) or multiparam-
etric MRI (mpMRI) are now able to detect clinically evident
disease with a rate up to 75% for 11C-choline-PET/CT at a
prostate speciﬁc antigen (PSA) value .3 ngml21.5 In up to
50% of patients with PET/CT-positive scans, isolated local
relapse is diagnosed.5
In the case of solid tumours, the approach to isolated local
relapse is local treatment [surgery, radiotherapy (RT) etc.],
whenever possible, and systemic therapy is rarely used. Par-
adoxically, in the case of prostate cancer local relapse, systemic
androgen deprivation therapy (ADT) is the standard-of-care
approach [National Comprehensive Cancer Network
(NCCN) guidelines].6 Such treatment has a mainly palliative
intent and is continued life long, giving rise to numerous side
effects, deterioration in the quality of life and high social costs.
According to the NCCN guidelines, a local approach including
surgery, cryotherapy or brachytherapy should be considered
for patients candidated for local salvage treatment: patients
with documented recurrent local disease of limited aggres-
siveness (low Gleason score, stage and initial PSA), a long time
interval between primary EBRT and recurrence and a slow
PSA evolution. Indeed, in this clinical scenario, effective local
therapy appears a more convenient strategy for controlling local
disease, and it reduces the burden of systemic therapy. Radical sal-
vage surgery is rarely used in this situation although recent studies
suggest that it is more effective than other salvage treatment mo-
dalities, such as cryotherapy, high-intensity focus ultrasound (HIFU)
or brachytherapy, in terms of biochemical control.7 The disadvan-
tage of salvage surgery includes the risk of severe perioperative and
post-operative complications owing to previous therapies and the
advanced age of the patients (comorbidities). Brachytherapy might
be an option for some patients, however low-dose-rate (LDR)
brachytherapy requires general anaesthesia and hospitalization. It is
important to note that modern technologies with image-guided
intensity-modulated RT (IG-IMRT) or stereotactic body RT (SBRT)
allow for the precise delivery of high radiation doses. Several dosi-
metric planning studies conﬁrm that the target dose distribution
might be similar between high-dose-rate brachytherapy and non-
invasive EBRT, such as CyberKnifeTM (Accuray, Sunnyvale, CA).8,9
Ablative hypofractionation regimens are commonly chosen for
high-precision RT, which may increase the chance of killing prostate
cancer cells, owing to their low alpha/beta ratio. Recently, several
reports on stereotactic prostate reirradiation have been published:
Vavassori et al10 reported the preliminary results on six patients
treated with Cyberknife SBRT (30Gy in ﬁve fractions over ﬁve
consecutive days). This study was later updated by Jereczek-Fossa
et al:11 complete response was obtained in six out of nine patients
(without any systemic therapy) with a low toxicity proﬁle (no rectal
toxicity and few urinary events). The pattern of failure was pre-
dominantly out of ﬁeld (four out of ﬁve events). The authors
concluded that CyberKnife reirradiation is a feasible and safe ap-
proach and offers excellent in-ﬁeld tumour control.
On this basis, we present a retrospective analysis of the series of
patients who underwent salvage re-EBRT using highly selective
modalities (IG-IMRT or SBRT) for local recurrence after radical
or post-prostatectomy/salvage RT.
METHODS AND MATERIALS
Study protocol
The inclusion criteria for this retrospective study were as follows:
(1) isolated local recurrence of prostate cancer after radical or
post-prostatectomy RT, (2) salvage re-EBRT performed in the
Radiotherapy Department of the European Institute of Oncology,
Milan, Italy, between February 2008 and October 2013, (3)
Table 1. Patient characteristics (N532 patients)
Characteristics All patients, N5 32
Age (years), at the re-EBRT
Mean6 standard deviation 736 5.96
Median (range) 73 (60–83)
Initial PSA (ngml21)* n5 31
Initial PSA (unknown) n5 1
Median (range) 15 (4.5–110.0)
Initial Gleason score* N5 29
Initial Gleason score (unknown) N5 3
Median (range) 6 (4–9)
Initial disease category (National
Comprehensive Cancer Network)6
N5 22a
Low 5
Intermediate 7
High 9
Unknown 1
Initial treatment
RT6ADT 10
Radical retropubic prostatectomy6
lymphadenectomy6ADT6RT
22
Interval between diagnosis of prostate cancer and re-EBRT
Mean (months) (range) 115 (33–182)
Former radiotherapy
External beam radiotherapy 29
Brachytherapy 3
ADT, androgen deprivation therapy; PSA, prostate specific antigen;
re-EBRT, external beam reirradiation; RT, radiotherapy.
*Data are available only for this number of patients and not for the 32
patients analysed.
aOperated patients excluded.
Table 2. Patient and external beam re-irradiation (re-EBRT)
characteristics (N532 patients)
Characteristics
Prostate,
n5 22
Prostate bed,
n5 10
Pre re-EBRT PSA (ngml21)
Median (range) 3.9 (0.8–16.9) 2.3 (0.7–51.8)
Biopsy of the target lesion
Yes 13 6
No 8 4
Unknown 1 0
ADT added to re-EBRT
Yes 8 3
Type of ADT added to radiotherapy
Complete androgen
blockade
3 2
Luteinizing hormone
releasing factor alone
2 1
Antiandrogen alonea 3 0
re-EBRT data
Median total dose (Gy) 25 (25–30) 25 (15–25)
Dose/fraction 5 (3–6) 5
Number of fractions 5 (5–10) 5 (3–5)
Mean overall re-EBRT
duration (days)
10 9
Median (days) 10 9
ADT, androgen deprivation therapy; PSA, prostate specific antigen.
aBicalutamide.
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minimum follow-up of 12months and (4) written consent for
re-EBRT and for the use of clinical data for scientiﬁc or educa-
tional purposes (anonymously). No other local therapy (surgery,
cryotherapy, HIFU etc.) for the recurrent lesion was permitted.
Radiotherapy procedures
The ﬁrst RT course included three-dimensional conformal RT
(3D-CRT) to 29 patients to a median dose of 74Gy (range,
50–80Gy). Three patients received an LDR brachytherapy im-
plant to a dose of 145Gy.
The re-EBRT technique was developed in the Radiotherapy
Department of the European Institute of Oncology, Milan, Italy.
First, image-guided 3D-CRT (IG-3D-CRT) was used: up to
December 2010, our standard treatment technique (i) consisted
of a three-dimensional conformal dynamic arc therapy with two
lateral arcs of 100° compass (220°–320° and 40°–140°). Treat-
ment was performed using three different modalities: the 15-MV
X-ray beam generated by our Saturno 43 (General Electric
Medical Systems) and equipped with the Elekta (Stockholm,
Sweden) micro-multileaf collimator (mMLC); the 6-MV X-ray
beam generated by a Clinac® 600 (Varian® Medical Systems,
Palo Alto, CA) and equipped with the M3® (BrainLab AG,
Feldkirchken, Germany) mMLC; the 18-MV X-ray beam
generated by a Clinac® 2100 (Varian® Medical Systems, Palo
Alto, CA) and equipped with the Millennium80® multileaf
collimator (MLC).
In 2010, IG-IMRTwith Rapid Arc® (Varian® Medical Systems, Palo
Alto, CA) was implemented with a treatment schedule of 25Gy in
ﬁve fractions, given every other day within an overall treatment
time of 10 days: the technique consisted of one or two coplanar
arcs: the ﬁrst arc was 280° wide (from 220° to 140°) with a 340°
collimator; the second one was 350° wide (from 175° to 185°) with
a 20° collimator. If two arcs were used, they were optimized si-
multaneously and rotated in opposite directions (clockwise and
counterclockwise). Collimator rotation was used to minimize the
tongue and groove effect during arc rotation and to make use of
leaf trajectories that are non-coplanar with respect to the patient’s
axis.12 In 2012, IG-IMRTwas implemented with VeroTM (BrainLab
AG, Feldkirchen, Germany) and CyberKnife™ and the same ﬁve-
fraction schedule was prescribed, although some modiﬁcations
(5–6Gy per fractions) were made according to the retreated vol-
ume, the interval between the two RT courses, the shape of the
recurrence and its localization, and the patient’s comorbidities.
Vero is a joint product of BrainLab AG and Mitsubishi Heavy
Industries Ltd (Tokyo, Japan). The Vero system is a small and light
6-MV C-band linear accelerator (linac) with a fast MLC mounted
on an O-ring gantry (BrainLab AG, Feldkirchken, Germany). The
MLC allows a maximum ﬁeld size of 150 by 150mm, and the
maximum leaf speed is 50mms21. Two orthogonal gimbals hold
the linac-MLC assembly, allowing pan and tilt motions of the linac
and therapeutic beam. This mechanism offers the possibility to
perform real-time tracking of moving tumours, decoupled from
the dynamic MLC and intensity modulation of the dose. The
maximum excursion of the beam axis is 4.4 cm at the isocentre
plane (or 2.5) in both pan and tilt directions.
In addition to an electronic portal imaging device for megavoltage
portal imaging, the Vero system is equipped with two orthogonal
kilovoltage imaging systems attached to the O-ring at 45° from the
megavoltage beam axis. This imaging system allows cone beam CT
(CBCT) and simultaneous acquisition of orthogonal radiographs
and ﬂuoroscopy. An ExacTrac (BrainLab AG) automated infrared
marker-based patient-positioning device is integrated into the
Vero system.
For CyberKnife SRT, Multiplan® v. 2.0.5 was employed. If feasible,
a radio-opaque ﬁducial marker was introduced into the target le-
sion. 1 week after the implant, a simulation CTscan was performed
using contrast medium. Gross tumour volume (GTV) was
Table 3. Treatment outcome (N532)
Outcome
Prostate,
n5 22
Prostate bed,
n5 10
Acute toxicity of re-EBRT
Urinary toxicitya 7 1
G1 5 1
G2 2 0
Rectal toxicitya 3 1
G1 3 0
G2 0 1
Late toxicity of re-EBRT
Urinary toxicitya 6 1
G1 6 0
G2 0 1
Not available (two patients)b
Rectal toxicitya 4 1
G1 4 1
Not available (two patients)b
Status at the last observation (September 2014)
No evidence of
disease
13
Alive with disease 15
Biochemical relapse 3
Clinical local relapse 4
Clinical locoregional
relapse
1
Clinical metastatic
relapse
7
Dead 4
Metastatic disease 2
Other tumour 1
Other cause 1
re-EBRT, external beam re-irradiation.
aAccording to Radiation Therapy Oncology Group/European Organi-
zation for Research and Treatment of Cancer criteria.12
bDeath of the patients before late toxicity check-point.
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contoured on the CT scan. A 1-mm margin was added to the GTV
to take account of submillimetre ﬁducial marker detection inac-
curacy. Fiducial marker detection was used to target the planning
target volume (PTV) during the treatment. For patients with no
ﬁducial marker, the Xsight® (Accuray, Sunnyvale, CA) spine
detecting system was used.
All patients underwent supine CT simulation, and for some
patients, fusion with mpMRI was carried out. All the patients were
treated with a full bladder (the patients were instructed to drink
0.5 l of water 1 h before starting the RT session) and to empty the
rectum (the patients had an enema before the CT simulation, and
this was repeated during the treatment if necessary, that is, when
the CBCT showed large rectal volume).13 The patients were asked
to follow dietary instructions given to them during the ﬁrst visit.
Clinical target volume (CTV) included the whole prostate or the
site of clinical nodule relapse in the prostatic bed [partial prostate
irradiation (PPI)]. In two patients, who underwent three courses
of RT, PPI was performed for the third course of RT. The
expansion from the CTV to the PTV varied according to the
technique and was in the range of 3mm posteriorly and 5mm in
the other directions for highly conformal techniques such as
Cyberknife or Vero, to 5mm posteriorly and 7mm in the other
directions for IG-3D-CRT. The organs at risk contoured included
the rectum (and the posterior part of the rectum for IMRT plans),
urinary bladder, penile bulb, penis, testis, femoral heads, peritoneal
cavity and cauda equina. Dose–volume histograms were based on
a previous study reported by Jereczek-Fossa et al11 and included
mean dose to 30% of the rectal volume (DR30), ,13.8Gy; mean
dose to 60% of the rectal volume (DR60),,6.69Gy; mean dose to
30% of the bladder volume (DB30), ,10.58Gy for prostate reir-
radiation; and mean DR30, ,8.4Gy; mean DR60, ,4.08Gy; and
mean DB30, ,3.94Gy for prostatic bed re-irradiation. These
constraints were applied in the later years of the study.
End points and patient monitoring
In order to diagnose isolated local recurrence of prostate cancer, in
the prostate or prostatic bed, staging was required and included
total body CT, 11C-choline PET/CT scan and pelvic MRI and, if
Table 4. Acute and late toxicities (only positive events registered) in relation to radiotherapy (RT) fractionation
Acute toxicity
RT fractionation
Number
of patients30Gy (63 5 fr),
number of patients 5
25Gy (53 5 fr),
number of patients 25
30Gy (33 10 fr), number
of patients 1
GU G1 0 5 1 6
GU G2 1 1 0 2
GI G1 0 3 0 3
GI G2 0 1 0 1
Late toxicity
RT fractionation Number
of patients30Gy (63 5 fr) number of patients 5 25Gy (53 5 fr) number of patients 25
GU G1 2 5 7
GU G2 0 1 1
GI G1 1 4 5
fr, fraction; GI, rectal and intestinal events; GU, genitourinary events.
Table 5. Acute and late toxicities (only positive events registered) with or without concomitant androgen deprivation therapy (ADT)
Acute toxicity
RT concomitant with ADT
Number of patients
Yes (patients 11) No (patients 21)
GU G1 2 4 6
GU G2 0 2 2
GI G1 1 2 3
GI G2 0 1 1
Late toxicity
RT concomitant with ADT
Number of patients
Yes (patients 11) No (patients 21)
GU G1 2 5 7
GU G2 0 1 1
GI G1 2 3 5
GI, rectal and intestinal events; GU, genitourinary events.
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possible, mpMRI. All patients were discussed on a multidisciplinary
basis, and were monitored clinically before and during RT. Fol-
lowing the course of treatment, the patients were seen by a radia-
tion oncologist every 6months and their PSA was tested every
3months. In the case of biochemical response (PSA reduction or
stabilization), no radiologic or nuclear medicine imaging evaluation
was requested.
Acute and late toxicity was the primary end point of the present study.
Toxicity was evaluated using Radiation Therapy Oncology Group/
European Organization for Research and Treatment of Cancer
guidelines.14 Biochemical response was evaluated according to the
Phoenix Consensus deﬁnition for prostate re-irradiation, that is, the
American Society for Radiation Oncology (ASTRO) deﬁnition.15 We
considered the NADIR12ng ASTRO deﬁnition as valid to deﬁne
biochemical failure also in the patients treated with concomitant ADT.
In post-prostatectomy patients, biochemical progression was
deﬁned as a continuous increase in PSA over the pre-re-EBRT
value (conﬁrmed by at least two tests). When possible, the ra-
diologic response was also evaluated.
RESULTS
Patient population
Between February 2008 and October 2014, 50 patients with local
prostate cancer relapse after a primary irradiation were treated
with re-EBRT at the Radiotherapy Department, European In-
stitute of Oncology, Milan, Italy. All patients gave written con-
sent for re-EBRT and for data analysis. 32 patients fulﬁlled the
inclusion criteria (treated up to October 2013, i.e. follow-up of
at least 12 months) and were the subjects of the present study.
The baseline characteristics of the patients at re-EBRT are listed
in Tables 1 and 2.
In 22 patients (68.7%), the ﬁrst RT course was delivered to the
prostate 6 seminal vesicle with radical intent, whereas 10
patients (31.3%) had previous surgery and were irradiated in
a post-operative or salvage setting.
A choline-PET/CT scan was performed and was positive in
28 patients. 14 patients also had a positive pelvic MRI (mpMRI
in 4 cases). Three patients had a positive MRI alone and one
patient had a CT and pelvic ultrasound that indicated the
presence of disease at a radiological level; the initial histology
and PSA evolution were considered, all suggesting local failure.
Biopsy was performed in 19/32 patients (59.3%) and was pos-
itive in 15 patients (46.8%). 17 patients with either no biopsy or
with a negative one were reirradiated on the basis of the ra-
diological diagnosis of isolated local recurrence: of these
patients, a positive choline-PET/CT scan; for 16 of them,
a positive pelvic MRI (mpMRI in 2 cases); and for 1, a pelvic CT
were carried out, all of which indicated local failure.
In all, re-EBRT included 3D-CRT with image-guided RT (IGRT),
SBRT, IMRT, SBRT1 IMRTand CyberKnife, respectively, in 1, 13,
15, 1 and 2patients. The schedules used are reported in Table 2; all
had treatment on alternate days: the choice of fractionation was
guided by the technological developments in our department
(availability of image guidance) and the favourable level of toxicity
observed in the ﬁrst patients of the current series. Then from 2012,
we introduced IG-IMRT hypofractionated schemes, regardless of
the relapse pattern (prostate or post-prostatectomy bed).
Three patients had a particular clinical course; two of them be-
cause they were irradiated three times: after a primary 3D-CRT,
they received EBRT1 brachytherapy boost. Both patients re-
ceived salvage re-EBRT with Cyberknife and IG-IMRT Vero,
respectively. Later, after a second biochemical and clinical re-
lapse, both patients underwent a re-EBRT with a new IG-IMRT
course. In this case, we censored the toxicity and tumour control
data after the second course of RT, in order to present the data in
a homogeneous way (the outcome of the ﬁrst re-irradiation).
The other patient had previously been treated with IG-IMRT for
lymph node recurrence with complete remission.
It is important to note that in the current series of patients, ADT
was permitted if prescribed earlier by the referring physician. In
these cases, it was continued until the completion of RT and then
stopped. Obviously, PSA NADIR was strongly inﬂuenced in the
ADT group, but we considered NADIR12ngml21 (ASTRO def-
inition) valid to deﬁne biochemical failure in this situation as well.
Toxicity of external beam reirradiation
The toxicity is reported in Table 3, the toxicity in relation to the
fractionation schedules is reported in Table 4, and, in Table 5,
Table 6. Outcome with or without concomitant androgen deprivation therapy
Number of patients Outcome
Radiotherapy concomitant with androgen deprivation therapy
Yes (number of patients, 11) No (number of patients, 21)
13 No evidence of disease 3 10
3 Biochemical relapse 1 2
4 Clinical local relapse 2 2
1 Locoregional relapse 0 1
7 Metastatic relapse 2 5
4 Deada 3 1
aOnly two patients died as a result of disease progression.
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the events registered with or without concomitant ADT: the re-
EBRT was well tolerated in the majority of the patients, with 24
(75%) and 28 (87.5%) patients free from acute urinary and
rectal events, respectively, and no grade 3 acute/late toxicity was
reported.
Tumour control data
At the median follow-up of 21.3months (range, 2–53months),
13 patients (40.6%) were alive with no evidence of disease
(NED), while 15 patients (46.9%) were alive with active disease
and 4 (12.5%) had died, 2 from metastatic progression, 1 from
a second tumour and with metastatic disease, 1 from an acute
ischaemic heart attack and NED.
Tumour progression (biochemical or clinical) was observed in
15patients: after a median period of 9.4months following the end
of re-EBRT for biochemical progression (range, 4.9–27.8months),
and after a median period of 13.2months following treatment for
clinical progression (range, 2–53months). At present, biochemical
failure alone has been reported in three males. Clinical progression
was present in 12 males: the pattern of failure included local pro-
gression in 4 males (30%) and regional or metastatic progression in
1 and 7 males, respectively. In all cases, clinical progression followed
biochemical progression.
11 patients received concurrent ADT during re-EBRT: Table 6
shows patient outcome with or without ADT.
DISCUSSION
Our series of 32 patients, all from the same hospital, showed that re-
EBRT for local relapse in prostate cancer, using highly selective
modalities, is feasible and very well tolerated, with the vast majority of
the patients free of acute or late side effects. Only single grade 2 events
were observed, and no severe (.grade 2) toxicity was reported.
This excellent toxicity proﬁle has to be compared with other local
salvage therapies, for both acute and late events. In the case of
salvage surgery, perioperative toxicity is common and correlated
mortality is a risk. As in the case of other focal therapies, anaes-
thesia is necessary, which can be contraindicated in some patients
because of their age and concomitant medical conditions.7 The late
toxicity proﬁle of re-EBRT is extremely favourable when compared
with late events reported following other local salvage therapies.
Tumour control in this unselected patient series was good, with
40.6% of the patients NED after a median follow-up of 21.3months
after re-EBRT. This compares well with the ﬁgures reported for
other local salvage therapies.4 Unfortunately, it is impossible to
compare patterns of failure and the degree of local control with
other local salvage therapies since this is rarely reported.4
In our series, local control was excellent with only four events of
local recurrence. The majority of patients with progressive disease
experienced metastatic dissemination. These ﬁndings may be at
least partially explained by the lack of strict inclusion criteria in our
series. In fact, not all our patients would be classiﬁed as good
candidates for local salvage treatment according to the NCCN
guidelines (indeed, one-third of the patients had high-risk disease
initially).6 However, these cases were discussed individually with
a multidisciplinary board and the patient, proposing salvage re-
EBRT as a way to postpone the systemic palliative approach or to
avoid an invasive local approach (surgery or brachytherapy). The
effect of the dose prescribed for re-EBRT also warrants further
investigation: the extremely low toxicity proﬁle observed in our
series raises the possibility of dose escalation. Concomitant ADT
was not seen to affect the re-EBRT outcome; however, this result
might be biased by the limited number of cases.
Our ﬁndings suggest that re-EBRTmight be a safe and non-invasive
alternative to other salvage modalities that are being investigated for
isolated primary recurrent prostate cancer, including prostatectomy,
brachytherapy, HIFU, cryotherapy, radiofrequency interstitial tu-
mour ablation and photodynamic therapy, with some of these
reporting severe late toxicities, including rectal ﬁstula after HIFU
and a high rate of rectal dysfunction, and urinary incontinence, or
retention, owing to urethral stricture, after cryotherapy.16
The strengths of our series include the use of modern selective RT
techniques (IGRT, SBRT, IMRT etc.). All cases were discussed in
the multidisciplinary setting both before re-EBRTand, if necessary,
after re-irradiation. We are well aware of the limitations of our
study, including short follow-up, the retrospective character of the
study, the limited number of patients, the heterogeneity of the
clinical cases (regarding previous therapies, concomitant systemic
treatment, type of previous RT etc.), RT techniques and doses.
Longer follow-up and a bigger patient series is warranted in
order to conﬁrm these promising early ﬁndings and better de-
ﬁne the category of patients that can really beneﬁt from a salvage
local procedure.17 More selective inclusion criteria and further
dose escalation might improve tumour control rates.
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